| 1.911 0.241 (14.43%) | 10-22 14:48 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.35 |
1-year : | 2.75 |
| Resists | First : | 2.01 |
Second : | 2.35 |
| Pivot price | 1.78  |
|||
| Supports | First : | 1.66 |
Second : | 1.44 |
| MAs | MA(5) : | 1.65 |
MA(20) : | 1.8 |
| MA(100) : | 3.71 |
MA(250) : | 7.28 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 51.8 |
D(3) : | 32.4 |
| RSI | RSI(14): 50 |
|||
| 52-week | High : | 16 | Low : | 1.44 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ELTX ] has closed below upper band by 26.4%. Bollinger Bands are 85.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 76 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.68 - 1.69 | 1.69 - 1.7 |
| Low: | 1.56 - 1.56 | 1.56 - 1.57 |
| Close: | 1.65 - 1.67 | 1.67 - 1.68 |
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
Thu, 13 Aug 2026
Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - Elicio Therapeutics
Sat, 25 Jul 2026
Elicio Therapeutics, Inc. Revenue Breakdown – NASDAQ:ELTX - TradingView
Thu, 02 Jul 2026
Another Blow For ELTX? Elicio Raises Fresh Capital Weeks After Trial Disappointment - Yahoo Finance
Wed, 01 Jul 2026
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering - Yahoo Finance
Mon, 29 Jun 2026
Elicio Therapeutics, Inc. (ELTX) Investigation: Bronstein, Gewirt - The National Law Review
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 26 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 26.9 (%) |
| Held by Institutions | 21 (%) |
| Shares Short | 1,550 (K) |
| Shares Short P.Month | 1,580 (K) |
| EPS | -2.17 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.36 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -77.9 % |
| Return on Equity (ttm) | -774.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.44 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -38 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -0.89 |
| PEG Ratio | 0 |
| Price to Book value | 5.29 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.33 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|